Encoded Therapeutics Announces FDA Alignment and Pivotal Study for ETX101 in Dravet Syndrome

요약

“FDA alignment achieved on pivotal study design supporting BLA submission for ETX101”
“30-patient pivotal study initiated to evaluate seizure reduction in children aged 6 months to <4 years”
“ETX101 selected for Presidential Symposium presentation at 2026 ASGCT Annual Meeting”

Debt neutral Cash good Valuation low Drawdown neutral Recent decline

Encoded Therapeutics, ETX101 드라베 증후군 치료제 FDA 승인 및 임상 연구 발표
ETX101 임상 연구 설계에 대한 FDA 승인 획득
6개월~4세 미만 아동 30명 대상 임상 연구 시작
2026 ASGCT 연례 학술대회 대통령 심포지엄 발표 선정

출처: Yahoo Finance
링크: https://finance.yahoo.com/sectors/healthcare/articles/encoded-therapeutics-announces-fda-alignment-120200979.html

소셜 공유 미리보기(OG) 전용 페이지입니다.